Article
Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.
Medicine - 8 Nov 2024
Yao Ling, Zhang Chunzhen, Li Dailong, Xu Lu, Yang Xianfei
Abstract excerpt
BACKGROUND: To systematically evaluate the efficacy and safety of osimertinib plus bevacizumab in treating advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. METHODS: Up to May 26, 2024, the databases of PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, Chinese Biomedical Literature, China Science and Technology Journal,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.